Pharvaris Sets Strategic Priorities for 2025
ZUG, Switzerland — Pharvaris (NASDAQ: PHVS), a pioneering biopharmaceutical firm, recently detailed its strategic priorities for 2025, reflecting its commitment to developing effective treatments for hereditary angioedema (HAE) and acquired angioedema (AAE). This year is deemed crucial for advancing clinical studies focused on deucrictibant, a novel oral bradykinin B2 receptor antagonist.
Advancing Clinical Development of Deucrictibant
As part of its strategic roadmap, Pharvaris has initiated the pivotal CHAPTER-3 Phase 3 study, aiming to gather critical data on deucrictibant’s potential in preventing HAE attacks. This trial is significant for its human-centric approach, with topline data expected in the latter half of 2026.
Understanding the CHAPTER-3 Study
CHAPTER-3 is designed to evaluate the efficacy of deucrictibant in individuals aged 12 years and up, emphasizing its role in prophylaxis against angioedema attacks. Approximately 81 participants will be enrolled in a randomized clinical format, comparing the innovative treatment against a placebo over a 24-week duration. This detailed assessment will measure the frequency of HAE attacks among other clinically relevant outcomes.
Progressing Other Clinical Studies
In addition to CHAPTER-3, enrollment for the RAPIDe-3 pivotal Phase 3 study, which investigates on-demand treatment for HAE attacks using deucrictibant, continues on track. The goal is to determine the rapidity of symptom relief and overall effectiveness of the treatment, with topline data anticipated in early 2026.
Expanding the Focus to Acquired Angioedema
Pharvaris is also laying groundwork to explore possibilities for treating acquired angioedema due to C1-INH deficiency (AAE-C1INH). The initiation of a new study for this indication is expected in 2025 and is part of the company’s strategy to address unmet needs surrounding angioedema.
Importance of Regulatory Insights
The company actively engages with regulatory authorities, including feedback from the FDA, to refine its clinical development plans for aiding those with AAE-C1INH. Pharvaris recognizes the absence of approved therapies for this condition, highlighting the importance of its research.
Financial Stability to Support Growth
Pharvaris currently maintains a robust financial standing, with sufficient resources allocated to sustain its strategic initiatives into the third quarter of 2026. This strong financial foundation empowers the team to progress with confidence as they navigate essential regulatory pathways.
Leadership and Team Expansion
To bolster preparations for the launch of deucrictibant, Pharvaris has expanded its team with industry experts in sales and marketing. Chris Wilson, recently appointed as Vice President of Sales & Marketing for North America, brings extensive experience in HAE product commercialization.
Industry Advocacy and Data Presentation
The organization is actively presenting insightful data concerning HAE treatment experiences at prominent medical forums. This information plays a vital role in highlighting the challenges faced by patients and caregivers, thus shaping future therapeutic approaches.
Upcoming Conferences and Presentations
Pharvaris will be participating in key investor conferences, including the J.P. Morgan Healthcare Conference, where CEO Berndt Modig will present insights about the company’s strategies and development plans. These engagements serve as platforms to provide updates to stakeholders and attract further interest in Pharvaris’ innovative therapies.
Future Presentations
At the forthcoming American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, Pharvaris will present new data surrounding the safety and efficacy profiles of deucrictibant, reflecting its commitment to continuous research and development. These engagements are crucial for sharing knowledge and promoting awareness of therapy needs within the angioedema community.
Conclusion: A Bright Future Ahead
Pharvaris looks forward to 2025 with optimism, prioritizing its mission to provide effective oral medications for managing angioedema. With its strong pipeline and experienced leadership team, the company is well-positioned to make significant strides in the field of bradykinin-mediated disorders.
Frequently Asked Questions
What are the main goals of Pharvaris for 2025?
Pharvaris aims to advance its clinical studies for deucrictibant, focusing on both prophylactic and on-demand treatment options for hereditary and acquired angioedema.
What is deucrictibant?
Deucrictibant is an oral bradykinin B2 receptor antagonist currently under investigation for its efficacy in preventing and treating HAE attacks.
When will data from the clinical studies be available?
Topline data from the CHAPTER-3 study is expected in late 2026, while results from the RAPIDe-3 study are anticipated in early 2026.
How is Pharvaris addressing acquired angioedema?
The company is planning to initiate a clinical study for AAE-C1INH by 2025, expanding its research efforts to address this unmet medical need.
What recent appointments have been made at Pharvaris?
Pharvaris has enhanced its leadership team by appointing Chris Wilson as Vice President of Sales & Marketing, emphasizing its focus on a successful product launch and growth strategy.
